GenoMed Inc has initiated discussions with the National Institutes of Health and the Centers for Disease Control (CDC) for assistance in the Company's world-wide clinical trial against SARS.

Dr. David Moskowitz, Chairman, CEO, and Chief Medical Officer of GenoMed, said, "GenoMed is extremely grateful to Dr. Laughlin and Grant for their generous comments, and to Steve Mitchell for his excellent reporting. I've just phoned and emailed Dr. Laughlin and Mr. Grant in an attempt to coordinate our activities as quickly as possible. This is one of those medical situations where every minute counts for patients with SARS or at high risk of getting it."

Dr. Moskowitz continued, "At GenoMed we believe that SARS has already shown itself to behave more like asthma than a bacterial pneumonia. Asthma consists of an exaggerated immune response oftentimes to a viral infection that's inconsequential for most people. Like SARS, asthma can kill if the immune response is excessive. The treatment for asthma is to suppress the immune response with inhaled or oral or occasionally intravenous steroids. In treating asthma, nobody even bothers trying to kill the virus which triggers the asthmatic attack. Most of the time we don't know which virus it is."